AAPG

NASDAQ 已收盘

Ascentage Pharma Group International

12.44 USD
▼-0.57-4.40%
盘后 12.67 +1.85%
2026-11-19
市值
$1.10B
市盈率
—
EPS
-2.33
股息率
—
52 周区间
12.44 – 33.09
成交量
1.49K
Beta
0.77
目标价
44.50
52W 低 12.4452W 高 33.09
价格走势

公司简介

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...